ER & HER2
* Tested using the MDA-MB-453 (low positive [~2-fold]) and SK-BR-3 (high positive [~10-fold]) cell lines
† Includes SNVs, CNAs, small indels and fusions
DefineMBC analyses a minimally invasive blood sample and provides a comprehensive clinical report that includes:
Determining HER2-low status requires evaluation of two components: protein for HER2 expression and DNA for ERBB2 gene amplification. Tissue testing evaluates protein expression by IHC and gene amplification by ISH. DefineMBC identifies HER2 protein expression using immunofluorescence on CTCs and assesses ERBB2 gene amplification using NGS on both CTCs and ctDNA.
1. Van Poznak C, Somerfield MR, Bast RC, et al. Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology Clinical Practice Guidelines. J Clin Oncol. Published July 20, 2015. 2015;33(24):2695-2704.doi:10.1200/JCO.2015.61.1459 2. Alba-Bernal A, Lavado-Valenzuela R, Domínguez-Recio ME, et al. Challenges and achievements of liquid biopsy technologies employed in early breast cancer. EBioMedicine. 2020;62:103100. doi:10.1016/j. ebiom.2020.103100 3. Tay TKY, Tan PH. Liquid biopsy in breast cancer. Arch Pathol Lab Med.2021;145(6):678-686. doi:10.5858/arpa.2019-0559-RA 4. Schrijver WAME, Suijkerbuijk KPM, van Gils CH, et al. Receptor conversion in distant breast cancer metastases: a systematic review and meta-analysis. J Natl Cancer Inst. 2018;110(6):568-580. doi:10.1093/jnci/djx273 5. Data on File. Epic Sciences. 6. Tarantino P, Hamilton E, Tolaney SM, et al. HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol. 2020;38(17):1951-1962. doi: 10.1200/JCO.19.02488. 7. Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9-10. DOI: 10.1056/NEJMoa2203690